Amgen announced that the US Food and Drug Administration (FDA) has approved Lumakras (sotorasib) in combination with Vectibix (panitumumab) for the treatment of adult patients with KRAS G12C-mutated ...

The FDA has approved Amgen’s Lumakras in combination with Vectibix (panitumumab) to treat adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) previously treated with ...

The US Food and Drug Administration (FDA) has approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for the treatment of certain adult patients with metastatic ...

THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with ...

FDA approved Amgen's Lumakras with Vectibix for KRAS G12C-mutated mCRC after prior chemotherapy, improving PFS to 5.6 months vs. 2 months. CodeBreaK 300 showed Lumakras plus Vectibix achieved a 26 ...

Amgen’s combination therapy has been approved by the US Food and Drug Administration (FDA) to treat a subset of colorectal cancer patients. Lumakras (sotorasib) and Vectibix (panitumumab) have been ...

Oct 22 (Reuters) - Amgen Inc:Boeing CEO to testify before US Senate commerce panel on April 2 Aerospace & Defense · February 14, 2025 · 6:39 PM PST Boeing CEO Kelly Ortberg will testify on April ...

News provided by Amgen Oct 22, 2023, 10:30 AM ET First Global Phase 3 Study in Patients with Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer Results Featured in a Presidential ...